A Phase III, Randomised, Double-Blind, Placebo-controlled, Event driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure

Prevention of Heart failure

Time to first occurrence of any of the components of the composite of: • Hospitalisation for HF • HF without hospitalisation • CV death

Time to first occurrence of any of the components of the composite of: • Hospitalisation for HF • CV death, Time to first occurrence of any of the components of the composite of: • Hospitalisation for HF • HF without hospitalisation, Time to CV death, Time to all-cause death, Time to first occurrence of any of the components of the composite of: • Stroke • CV death, Time to first occurrence of any of the components of the composite of: • New diagnosis of atrial fibrillation • CV death, Time to first occurrence of any of the components of the composite of: • MI • CV death

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Slovakia, Spain, Sweden